Zyversa Therapeutics, Inc. (ZVSA) — SEC Filings
Zyversa Therapeutics, Inc. (ZVSA) — 40 SEC filings. Latest: 8-K (Dec 3, 2025). Includes 19 8-K, 5 10-Q, 4 DEF 14A.
View Zyversa Therapeutics, Inc. on SEC EDGAR
Overview
Zyversa Therapeutics, Inc. (ZVSA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 3, 2025: ZyVersa Therapeutics, Inc. filed an 8-K on December 3, 2025, reporting on the departure of directors or certain officers, the election of directors, and the appointment of certain officers. The filing also covers compensatory arrangements for certain officers. The company, formerly Larkspur Health A
Sentiment Summary
Across 40 filings, the sentiment breakdown is: 9 bearish, 28 neutral, 3 mixed. The dominant filing sentiment for Zyversa Therapeutics, Inc. is neutral.
Filing Type Overview
Zyversa Therapeutics, Inc. (ZVSA) has filed 19 8-K, 5 10-Q, 2 S-1/A, 1 S-1, 4 DEF 14A, 2 10-K, 4 SC 13G/A, 1 10-K/A, 1 DEFA14A, 1 SC 13G with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (40)
Risk Profile
Risk Assessment: Of ZVSA's 35 recent filings, 10 were flagged as high-risk, 17 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$24,273,806 |
| Cash Position | $527,978 |
| Total Assets | $1,040,260 |
Key Executives
- Stephen C. Glover
- Faith L. Charles
- Todd Mason
Industry Context
The biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like ZyVersa often rely on substantial external funding to advance their pipelines. The competitive landscape is intense, with many companies vying for funding and market share, making successful commercialization critical.
Top Tags
corporate-governance (7) · delisting (5) · equity-sale (5) · listing-standards (4) · SEC Filing (4) · Biotech (4) · corporate-filing (4) · material-agreement (4) · proxy-statement (4) · leadership-change (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $24.3M | for the nine months ended September 30, 2025, significantly higher than $7.99M in 2024 |
| Impairment of In-Process R&D | $18.6M | major non-cash charge contributing to the net loss |
| Cash Balance | $0.5M | as of September 30, 2025, down from $1.53M at year-end 2024 |
| Working Capital Deficit | $11.8M | as of September 30, 2025, indicating severe liquidity issues |
| Accumulated Deficit | $136.9M | as of September 30, 2025, reflecting historical losses |
| Cash Used in Operations | $4.7M | for the nine months ended September 30, 2025 |
| Shares Outstanding | 8,095,921 | as of November 17, 2025, up from 2,508,191 at December 31, 2024, indicating dilution |
| Net Cash from Financing | $3.7M | for the nine months ended September 30, 2025, primarily from warrant exercises and private placements |
| Cash on Hand | $72,086 | Represents a 95.29% decrease from $1,530,924 at December 31, 2024, indicating severe liquidity issues. |
| Net Loss (Six Months) | $4.47M | While an improvement from $5.59M in 2024, it still reflects significant cash burn for a company with minimal cash. |
| Net Loss Improvement | 20.08% | Percentage decrease in net loss from $5.59 million to $4.47 million for the six months ended June 30, 2025, compared to 2024. |
| Operating Expense Reduction | 24.95% | Percentage decrease in total operating expenses from $5.58 million to $4.19 million for the six months ended June 30, 2025, compared to 2024. |
| Common Shares Outstanding | 8,095,921 | As of August 7, 2025, reflecting potential dilution from recent equity activities. |
| Registration Statement Number | 333-288470 | Identifies the specific S-1 filing being amended |
| Filing Date | 2025-08-01 | Date the S-1/A was filed with the SEC |
Forward-Looking Statements
- {"claim":"ZyVersa Therapeutics' stock price may experience downward pressure due to the institutional exit.","entity":"ZyVersa Therapeutics, Inc.","targetDate":"Q1 2024","confidence":"medium"}
- {"claim":"Other institutional investors might re-evaluate their positions in ZyVersa Therapeutics.","entity":"Institutional Investors","targetDate":"Q2 2024","confidence":"low"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Zyversa Therapeutics, Inc. (ZVSA)?
Zyversa Therapeutics, Inc. has 40 recent SEC filings from Jan 2024 to Dec 2025, including 19 8-K, 5 10-Q, 4 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ZVSA filings?
Across 40 filings, the sentiment breakdown is: 9 bearish, 28 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Zyversa Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Zyversa Therapeutics, Inc. (ZVSA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Zyversa Therapeutics, Inc.?
Key financial highlights from Zyversa Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ZVSA?
The investment thesis for ZVSA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Zyversa Therapeutics, Inc.?
Key executives identified across Zyversa Therapeutics, Inc.'s filings include Stephen C. Glover, Faith L. Charles, Todd Mason.
What are the main risk factors for Zyversa Therapeutics, Inc. stock?
Of ZVSA's 35 assessed filings, 10 were flagged high-risk, 17 medium-risk, and 8 low-risk.
What are recent predictions and forward guidance from Zyversa Therapeutics, Inc.?
Recent forward-looking statements from Zyversa Therapeutics, Inc. include guidance on {"claim":"ZyVersa Therapeutics' stock price may experience downward pressure due to the institutional exit.","entity":"Z and 1 other predictions.